Abstract
Purpose :
To characterize the clinical outcomes of a novel ab interno minimally invasive
procedure with the STREAMLINE ® Surgical System for creation of incisional goniotomies and
canal of Schlemm viscodilation in eyes with mild to severe primary open-angle glaucoma
(POAG).
Methods :
This was a retrospective analysis of all cases performed and followed up to 12
months. All eyes underwent creation of incisional goniotomies and canal of Schlemm
viscodilation following phacoemulsification cataract extraction. The angle surgery portion was
performed with a single-use handpiece tipped with a microcannula that creates precise
goniotomies through the trabecular meshwork into the canal of Schlemm and delivers a small
volume of ophthalmic viscosurgical device directly into the canal via precise catheterization.
Results :
Mean preoperative IOP was 16.9 mmHg using a mean of 1.2 medications. At 30 days
post-op, mean IOP was 15.3 mmHg using a mean of 0.2 medications; at 6 months, mean IOP
was 15.6 mmHg using a mean of 0.2 medications; and at 12 months, mean IOP was 17 mmHg
using a mean of 0.2 medications. At 30 days post-op, 21.6% (11/51) had IOP reduction ≥20%
from baseline, and 90.2% (46/51) were medication-free; at 6 months, 21.6% (11/51) had IOP
reduction ≥20% from baseline, and 90.2% (46/51) were medication-free; and at 12 months,
37.3% (19/51) had IOP reduction ≥20% from baseline, and 88.2% (45/51) were medication-free.
No adverse events were reported.
Conclusions :
Transluminal dilation of the canal of Schlemm using the STREAMLINE Surgical
System combined with phacoemulsification safely and effectively reduced both IOP and
dependence on IOP-lowering medications in eyes with mild to severe POAG extraction through
the first 12 months of follow-up.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.